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ORIGINAL ARTICLE
Hemophagocytosis in Cutaneous Autoimmune Disease
Katrin Kerl, MD,* Ingrid H. Wolf, MD,† Lorenzo Cerroni, MD,† Peter Wolf, MD,† Lars E. French, MD,*
and Helmut Kerl, MD†
Background: The signiﬁcance of the histological visualization of
hemophagocytosis in tissues depends on the context, varying from
a nonspeciﬁc phenomenon to a characteristic or diagnostic feature
for certain disease entities. Hemophagocytosis is also one of the
key features of macrophage activation syndrome (MAS) (hemo-
phagocytic syndrome) a potentially life-threatening complication
of underlying conditions such as infections, malignancy, and
autoimmune disorders. Clinical manifestations of MAS are high
fever, pancytopenia, liver dysfunction, and coagulopathy. These
clinical symptoms are due to an abnormal activation of the immune
system in a strong association with the cytokine milieu. The
diagnosis of MAS may be easily missed; it is usually detected in
the bone marrow, lymph node, liver, and spleen. Only few reports
exist in the literature with histological description of cutaneous
hemophagocytosis as a sign for MAS in patients with lymphoma
and infection. In this report, the authors present the clinicopatho-
logical and immunohistochemical features of 3 patients with
cutaneous hemophagocytosis, speciﬁcally erythrophagocytosis,
associated with autoimmune disease, and discuss the relevance of
these ﬁndings.
Observation: The authors report 3 patients who developed
cutaneous hemophagocytosis during the course of an underlying
autoimmune disorder. One patient suffered from dermatomyositis,
the other 2 patients from systemic lupus erythematosus, whereby
one of them was a 3-month old girl with neonatal lupus
erythematosus. The patient with dermatomyositis developed
MAS according to the current diagnostic criteria. Although the 2
other patients had an acute ﬂare of their autoimmune disease with
histological signs of cutaneous hemophagocytosis, they did not
fulﬁll the complete criteria for a diagnosis of MAS. Histiocyte
proliferation and activation with increase of cytokines could be
demonstrated by immunohistology.
Conclusions: This report is the ﬁrst to describe hemophagocytosis
in cutaneous biopsies of patients with autoimmune diseases,
associated with a complete or incomplete constellation of MAS.
Key players in this process are histiocytes/macrophages engaged in
phagocytosis of erythrocytes. Hemophagocytosis observed in skin
biopsies may be a diagnostic clue for MAS and an indicator for
a potentially aggressive course of the underlying disease.
Key Words: hemophagocytosis, macrophage activation syndrome,
autoimmune disease
(Am J Dermatopathol 2014;0:1–5)
INTRODUCTION
Hemophagocytosis is the process of engulfment of blood
cells, in particular erythrocytes, by histiocytes through the cell-
surface scavenger receptor CD1631 and is a histological feature
of selected diseases, including infections and malignancy. He-
mophagocytosis is only rarely observed in the skin, and its
signiﬁcance is variable. It may be a characteristic well-
known histological feature of certain entities such as primary
cutaneous g/d T-cell lymphoma, intravascular large B-cell
lymphoma, or Rosai–Dorfman disease, but it may also repre-
sent a nonspeciﬁc phenomenon, for example, in the late stage
of hemorrhagic disorders. When hemophagocytosis arises in
the context of systemic symptoms, it may also be a key feature
indicative of a severe and potentially life-threatening condition
characterized by a hyperactivation of the immune system and
excessive secretion of cytokines. This syndrome has been re-
ported under different names in the literature, including hemo-
phagocytic syndrome and secondary hemophagocytic
lymphohistiocytosis, and it belongs to the spectrum of macro-
phage associated histiocytoses2,3; the primary or familial form
is a genetic disorder with mutations in the perforin gene or in
genes implicated in the exocytosis of cytotoxic granules from
cytotoxic T lymphocytes.4 The secondary form occurs as
a severe complication of an underlying disorder and was ﬁrst
reported in patients with different types of infection5 and
malignancies, lymphomas in particular.6 Macrophage activa-
tion syndrome (MAS) is the term applied for hemophagocytic
syndrome occurring in the context of autoimmune disease. In
1991, Wong et al7 reported patients with active systemic lupus
erythematosus, whose bone marrow biopsies revealed hemo-
phagocytosis. Since then, MAS has been reported in the con-
text of several autoimmune diseases including systemic onset
juvenile rheumatoid arthritis, systemic lupus erythematosus,
dermatomyositis, progressive systemic sclerosis, and mixed
connective tissue disease.8–13 It has also been observed in Still
disease, a disorder now recognized to belong to the group of
auto-inﬂammatory diseases involving a dysregulation of the
innate immune system.14,15
The clinical symptoms of MAS are due to an uncon-
trolled and excessive activation of the immune system with
a proliferation of stimulated histiocytes and lymphocytes and
enhanced secretion of pro-inﬂammatory cytokines such tumor
necrosis factor alpha (TNF-a), interferon-g (IFN-g),
interleukin-6 (IL-6), and IL-1b.16 This cytokine storm leads
From the *Department of Dermatology, University Hospital of Zurich, Zürich,
Switzerland; and †Department of Dermatology, Medical University of
Graz, Graz, Austria.
The authors declare no conﬂicts of interest.
Reprints: Katrin Kerl, MD, Department of Dermatology, University Hospital
of Zurich, CH-8091 Zurich, Switzerland (e-mail: katrin.kerl@usz.ch).
© 2014 Lippincott Williams & Wilkins
Am J Dermatopathol  Volume 0, Number 0, Month 2014 www.amjdermatopathology.com | 1
Copyright ª Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
to a sepsis-like clinical presentation with high fever, hepatos-
plenomegaly, cytopenia, disseminated intravascular coagula-
tion, and neurological symptoms. Characteristic laboratory
ﬁndings of MAS include anemia, and thrombocytopenia, hy-
poﬁbrinogenemia, elevation of ferritin, and liver enzymes.
Hemophagocytosis in different organs is an important crite-
rion for the diagnosis of MAS, although its presence or the
proof of its existence is not mandatory for establishing the
diagnosis. Speciﬁc diagnostic criteria for MAS have been
suggested17,18 and are summarized in Table 1.
We demonstrate for the ﬁrst time hemophagocytosis
(erythrophagocytosis) in skin specimens of 3 patients with
autoimmune disease. One patient with dermatomyositis
showed acute and severe aggravation of his illness and fulﬁlled
the criteria for the diagnosis of MAS. In 2 patients with
systemic lupus erythematosus, hemophagocytosis in the skin
was not associated with the full clinical presentation of MAS.
OBSERVATIONS
Clinical Findings
Patient 1
A 62-year-old patient presented with high fever,
lethargy, muscle weakness, excessive edema with violaceous
discoloration, echymosis, ulceration and crusting of the
periorbital regions (Fig. 1). Gottron papules were obvious
over knuckles and interphalangeal joints. Internal investiga-
tions and laboratory tests revealed: elevation of muscle and
liver enzymes, pancytopenia, splenomegaly, lymphadenopa-
thy, elevated ferritine, and hypertriglyceridemia.
Electromyography showed signs of myositis. Bone
marrow biopsy failed to exhibit macrophage proliferation
and hemophagocytosis. Based on these ﬁndings together with
the skin biopsy (see below), a diagnosis of dermatomysitis
complicated by MAS was made. The general condition of the
patient deteriorated rapidly, and he died a few days after
hospital admission.
Patient 2
A 29-year-old woman with long standing systemic
lupus erythematosus displayed annular and polycyclic
lesions with scaly borders on the trunk and extensor surfaces
of the arms (Fig. 2). In addition, a butterﬂy rash on the face
and nail fold erythema could be observed. She complained
also of fatigue and joint pain. Laboratory tests revealed
positive results for antinuclear antibodies, anti-dsDNA
TABLE 1. Diagnostic Guidelines for Macrophage Activation
System Complicating Systemic Juvenile Idiopathic Arthritis
Laboratory criteria
Decreased platelet count (#262 · 109/L)
Elevated levels of aspartate aminotransferase (.59 U/L)
Decreased white blood cell count (#4.0 · 109/L)
Hypoﬁbrinogenemia (#2.5 g/L)
Clinical criteria
Central nervous system dysfunction (irritability, disorientation, lethargy,
headache, seizures, coma)
Hemorrhages (purpura, easy bruising, mucosal bleeding)
Hepatomegaly ($3 cm below the costal arch)
Histopathological criterion
Evidence of macrophage hemophagocytosis in the bone marrow aspirate
The diagnosis of MAS requires the presence of any 2 or more laboratory criteria or
of any 2 or 3 or more clinical and/or laboratory criteria.
Adapted from Ravelli et al. J Pediatr. 2005.16,17 Adaptations are themselves works
protected by copyright. So in order to publish this adaptation, authorization must be
obtained both from the owner of the copyright in the original work and from the owner
of copyright in the translation or adaptation.
FIGURE 1. Patient 1. Autoimmune hemophagocytic syn-
drome. A 62-year-old man with dermatomyositis complicated
by MAS. Excessive swelling, violet color, hemorrhage, and
crusting of the eyelids and the periorbital region.
FIGURE 2. Patient 2. Systemic lupus erythematosus showing
annular and polycyclic lesions with a scaly border on the arm.
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antibodies, anti-Ro/SSA antibodies, proteinuria, and low
serum complement levels.
Patient 3
A 3-month-old girl presented with disseminated
reddish-brown lesions on the head and trunk. Periorbital
scaly erythematous conﬂuent patches were also observed
(“raccoon eye” appearance). Other relevant ﬁndings were
antinuclear antibodies, anti-Ro/SSA, and anti-La/SSB posi-
tive; atrioventricular heart block, ﬁrst degree. Diagnosis was
neonatal lupus erythematosus.
Histological and Immunohistological Findings
Skin biopsy specimens were embedded in parafﬁn and
Hematoxilin-Eosin-staining was performed. In addition, the
following markers used for the assessment of monocyte–mac-
rophage activation were studied: CD163 (for M1 and M2,
macrophage subpopulations, Leica, clone 10D6 Germany),
TNF-a (R&D Systems, mouse monoclonal, clone 28401,
England, United Kingdom), IFN-g (rabbit polyclonal; Abcam,
England, United Kingdom), IL-6 (rabbit polyclonal; Abcam),
and IL-1b (rabbit polyclonal; Abcam) were performed in the
skin biopsies of patients 1 and 2.
Patient 1
A biopsy from the periorbital region revealed focally
smudged appearance of the dermoepidermal junction, mas-
sive edema in the upper dermis, plenty of erythrocytes,
proliferation of vessels, and an inﬁltrate predominated by
histiocytes/macrophages with fewer lymphocytes. Most nota-
ble was that a considerable number of the macrophages
displayed erythrophagocytosis (Figs. 3A–D).
A second biopsy from a Gottron papule on the left dorsal
hand showed hyperkeratosis, basal vacuolar changes and a thick-
ened basement membrane, a few dyskeratotic keratinocytes,
ectatic vessels, and a sparse superﬁcial inﬂammatory inﬁltrate.
FIGURE 3. Patient 1. A, Periorbital biopsy. Increased number of histiocytes/macrophages in edematous dermis. B and C, Arrows
indicate macrophages ingesting erythrocytes (hemophagocytosis).
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Patient 2
A biopsy from the left arm showed characteristic
epidermal changes of lupus erythematosus. Striking features
were a marked edema in the upper dermis with hemorrhage
and numerous macrophages engaged in phagocytosis of
erythrocytes (Figs. 4A–C).
Imunohistochemical analysis [performed in patient 1 on
the face biopsy (Fig. 5A), patient 2 on the arm biopsy] revealed
numerous CD163-positive macrophages within the upper
dermis. In addition, a high expression of IL-6, TNF-a, IFN-g,
and IL-1b could be detected in these cells.
Patient 3
A biopsy from the trunk featured a thinned epidermis
with scale crusts, basal vacuolar alteration, necrotic kerati-
nocytes, dermal edema, erythrocyte extravasation, and
lymphohistiocytic inﬁltrates with neutrophils. Again, most
remarkable was the identiﬁcation of macrophages containing
phagocyted red blood cells.
DISCUSSION
Here, we describe the clinical, histopathological, and
immunohistochemical features of 3 patients with cutaneous
hemophagocytosis in the context of underlying autoimmune
disease (systemic lupus erythematosus and dermatomyositis),
associated with MAS in 1 case.
Hemophagocytosis is a phenomenon that is only rarely
observed in the skin, and its signiﬁcance is dependent on the
clinicopathological context. It is a hallmark feature of MAS,
a potentially life-threatening syndrome complicating malig-
nancies, infections, and autoimmune disease.
Although hemophagocytosis is typical for MAS, its mere
presence is not automatically synonymous with MAS. Hemo-
phagocytosis may be absent in MAS and Hemophagocytic
syndrome, especially in the initial stages. However, it may
occur as a nonspeciﬁc phenomenon in various context as blood
transfusions, infection, autoimmune disease, and other causes
of red blood cell destruction. Recently, 2 articles reported
perivascular hemophagocytosis with signs of vasculitis in skin
biopsies of patients without the full clinical presentation of
MAS. The authors discuss the possibility of hemophagocytosis
as a sign of incomplete MAS versus it being simply a non-
speciﬁc sign of leucocytoclastic vasculitis.19,20
In our patients, the skin biopsies were performed at the
moment of an acute ﬂare in the activity of their underlying
autoimmune disease. One of the patients was then diagnosed
with MAS; the ﬁnding of hemophagocytosis in the skin
biopsy of this patient was an important additional clue to the
diagnosis.
The signiﬁcance of the ﬁnding of hemophagocytosis in
the skin biopsies of our 2 patients with systemic lupus
erythematosus, who did not have all criteria required for the
classiﬁcation as MAS is more difﬁcult to evaluate. It might be
interpreted as a sign of disease activity as it was associated
with a ﬂare. Further observations are required to clarify the
signiﬁcance of the cutaneous hemophagocytic process in
autoimmune disease without full clinical evidence of MAS.
Interestingly, a proliferation of a signiﬁcant number of
CD163-positive histiocytes/macrophages could be demonstrated
FIGURE 4. Patient 2. Biopsy from
the arm. A, Markedly edematous
papillary dermis with proliferation of
histiocytes and extravasated eryth-
rocytes. B and C, Arrows indicate
hemophagocytosis. Note apposition
of erythrocytes to macrophage in
Fig. 4C.
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within the dermis. CD163 is a hemoglobin–haptoglobin scav-
enger receptor and a lineage speciﬁc marker for histiocytes in
MAS. The soluble form of CD163 has been identiﬁed as a poten-
tial marker for the diagnosis of MAS.1
We also analyzed the pattern of cytokine expression in
the skin biopsy specimens of our patients 1 and 2 and found
overproduction of cytokins such as TNF-a, IFN-g, IL-6, and
IL-1b, showing evidence of activation of histiocytes. These
cytokines have been demonstrated to play a crucial role in the
pathogenesis of MAS16 and can induce hemophagocytosis.
In conclusion, this is the ﬁrst description of hemopha-
gocytosis in skin biopsies of patients with autoimmune
diseases, delivering also evidence on the involvement of
cytokine-producing activated macrophages. The diagnosis
of MAS is often challenging and may be delayed or even
missed because of the fact that there may be overlapping
clinical features with the underlying autoimmune disorder.
The presence of hemophagocytosis, without being speciﬁc
or mandatory for the diagnosis of MAS, is a very important
clue and is usually observed in biopsies of lymphoid tissues.
However, hemophagocytosis observed in skin biopsies can
also be a sign of MAS. Demonstration of hemophagocytosis
in skin biopsies may help to establish the diagnosis of MAS
and also potentially indicate a more severe course of the
underlying disorder. It should also provide new insights in
the mechanisms of host defense and the pathogenesis of
autoimmune disease.
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FIGURE 5. Immunohistological analysis. A, High proportion of
CD163-positive activated histiocytes/macrophages (patient 1).
B, Strong expression of IL-1b and TNF-a in histiocytes/
macrophages (patient 2).
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